Micafungin

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Candidiasis, Systemic

Conditions

Candidiasis, Systemic, Candida Meningitis

Trial Timeline

May 30, 2015 → Apr 10, 2018

NCT ID

NCT03421002

About Micafungin

Micafungin is a phase 2 stage product being developed by Astellas Pharma for Candidiasis, Systemic. The current trial status is completed. This product is registered under clinical trial identifier NCT03421002. Target conditions include Candidiasis, Systemic, Candida Meningitis.

What happened to similar drugs?

5 of 20 similar drugs in Candidiasis, Systemic were approved

Approved (5) Terminated (4) Active (12)

✅Fluconazole + MicafunginAstellas PharmaApproved

✅Caspofungin + Normal SalineMerckApproved

✅VoriconazolePfizerApproved

✅Eraxis (anidulafungin) + Diflucan (fluconazole) + Vfend (voriconazole)PfizerApproved

✅Clotrimazole vaginal tablet + FluconazoleBayerApproved

🔄Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3

🔄Micafungin + fluconazoleAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03174457	Pre-clinical	Completed	Jun 21, 2017	May 31, 2018	Invasive Fungal Infections
NCT03102658	Approved	Completed	Jan 1, 2017	Jul 1, 2017	Morbid Obesity
NCT02440178	Phase 2	Completed	Sep 19, 2015	Jun 1, 2017	Acute Leukemia
NCT03421002	Phase 2	Completed	May 30, 2015	Apr 10, 2018	Candidiasis, Systemic
NCT02678598	Pre-clinical	Completed	Mar 1, 2015	Aug 1, 2015	Invasive Fungal Infections
NCT02127788	Pre-clinical	Completed	Jul 3, 2014	Jan 27, 2016	Antifungal Prophylaxis
NCT02646800	Approved	Terminated	Mar 21, 2014	Dec 21, 2014	Aspergillosis
NCT02646774	Approved	Terminated	Mar 1, 2014	Jun 26, 2015	Invasive Aspergillosis
NCT02057289	Phase 1	Terminated	Jan 1, 2014	Nov 1, 2014	Immunocompromised
NCT01982071	Approved	Terminated	Sep 26, 2013	Aug 28, 2015	Candidemia
NCT01135589	Approved	UNKNOWN	Apr 1, 2010	May 1, 2012	Neutropenia
NCT00606268	Phase 1	Completed	Nov 1, 2007	Mar 1, 2009	Fungal Infections
NCT00608335	Phase 1	Completed	Oct 14, 2007	Sep 8, 2011	Oropharyngeal Candidiasis
NCT00818584	Phase 1	Completed	Aug 1, 2007	Oct 1, 2007	Candida
NCT00842504	Phase 1	Completed	Jul 1, 2007	Dec 1, 2009	Fungal Infection

Competing Products

20 competing products in Candidiasis, Systemic

See all competitors

Product	Company	Stage	Hype Score
Micafungin	Astellas Pharma	Phase 1	29
Isavuconazole + Caspofungin + Voriconazole	Astellas Pharma	Phase 3	40
Micafungin + fluconazole	Astellas Pharma	Phase 3	40
Micafungin (Mycamine)	Astellas Pharma	Phase 1	29
Fluconazole + Micafungin	Astellas Pharma	Approved	35
Micafungin + Caspofungin	Astellas Pharma	Phase 3	40
Micafungin + Fluconazole	Astellas Pharma	Phase 3	40
micafungin + caspofungin	Astellas Pharma	Phase 3	40
micafungin + amphotericin B deoxycholate	Astellas Pharma	Phase 3	32
FK463	Astellas Pharma	Phase 2	35
Micafungin + Liposomal Amphotericin B	Astellas Pharma	Phase 3	40
SHR8008 + Fluconazole	Jiangsu Hengrui Medicine	Phase 3	36
SHR8008 capsule + Fluconazole capsule	Jiangsu Hengrui Medicine	Phase 3	36
L-743,872	Merck	Pre-clinical	26
Caspofungin	Merck	Phase 2	35
L-743,872	Merck	Phase 2	27
Caspofungin + Amphotericin B Deoxycholate	Merck	Phase 2	27
Caspofungin acetate + Placebo	Merck	Phase 2	27
Caspofungin + Normal Saline	Merck	Approved	43
caspofungin acetate	Merck	Phase 3	40